Abstract 1897
Background
nab-P and Erib are approved for ≥ 2L treatment (Tx) of MBC. However, no data are available on comparative effectiveness of nab-P vs Erib for 2L Tx of MBC in the real-world setting.
Methods
Fully de-identified data from a US electronic medical record platform of 1300 community (not university-based) oncologists were used in this retrospective study of women aged ≥ 18 yrs with MBC who started nab-P or Erib monotherapy as 2L Tx from 12/1/10 to 4/6/15 (≥ 1 cycle of nab-P or Erib required to be included). Time to Tx discontinuation (TTD, day 1 to last date + 7 days for 7-day cycle and day 1 to last date + 21 days for 21-day cycle) and time to next Tx (TTNT; day 1 of line 2 to day 1 of line 3) were the primary objectives. Adverse events (AEs) and supportive care were also examined. Subset analyses examined outcomes in pts with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) or triple-negative (TN) MBC.
Results
This analysis included 176 pts (107 treated with nab-P and 69 with Erib). Baseline characteristics were similar between groups except that more pts treated with 2L nab-P had HR+ disease (P = 0.02) and were on combination Tx with a targeted agent (P = 0.03). More pts in the Erib group had used a taxane prior to MBC diagnosis (P = 0.01 for ≤ 1 year). Few pts with TN MBC were treated with 2L nab-P or Erib (Table). Overall, nab-P was associated with numerically longer TTD and TTNT vs Erib. AE rates were similar except that thrombocytopenia occurred more often with Erib. Antiemetics (IV) and G-CSF were used less often with nab-P. Steroids were used less often with Erib. Similar trends were reported in pts with HR + /HER2− or TN MBC.
nab-P n = 107 | Eribulin n = 69 | Unadjusted P Value | Adjusted P Value | |||
---|---|---|---|---|---|---|
Overall population | ||||||
Age, mean, years | 60 | 61 | 0.688 | - | ||
Schedule, weekly, % | 75 | - | - | - | ||
TTD, median, mos | 4.0 | 3.1 | 0.074 | 0.507 | ||
TTNT, median, mos | 6.0 | 4.7 | 0.538 | 0.759 | ||
Any grade AE in > 5% pts, % | ||||||
Anemia | 28.0 | 42.0 | 0.055 | 0.130 | ||
Neutropenia | 18.7 | 23.2 | 0.470 | 0.376 | ||
Thrombocytopenia | 7.5 | 18.8 | 0.023 | 0.107 | ||
Nausea + vomiting | 11.2 | 5.8 | 0.222 | 0.299 | ||
Dehydration | 8.4 | 2.9 | 0.205 | - | ||
Fatigue | 2.8 | 7.2 | 0.266 | - | ||
Pain | 2.8 | 7.2 | 0.266 | - | ||
Supportive Care doses/pt/100 days | ||||||
Antimetic (IV Only) | 5.77 | 6.92 | ConclusionsIn this US-based, real-world analysis, TTD and TTNT were numerically longer with nab-P compared with Erib, including in the HR + /HER2− and TN subsets. AEs were similar between the 2 groups. Pts receiving nab-P required less supportive care. Clinical trial identificationThis study is a retrospective analysis, therefore the protocol number and release data is not applicable. Legal entity responsible for the studyMonika Parisi, MPH FundingCelgene Corporation DisclosureM. Parisi, S. Glück, C. Pelletier, Q. Ni: Mr: Employee of Celgene Corporation. F. Braiteh: AbbVie, ActiveBiotech, Amgen, AstraZeneca, Bayer, BMS, BIND, BioMarin, BioTheranostics, BN Therapeutics, BI, Caris, Cell Therapeutics, Celgene, Daiichi, Dendreon, Genomic Health, Gilead, GSK, Halozyme, Heron, Eli Lilly, Incyte, Insys, Novartis, Pfizer, etc. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|